Sage shares surge as depression drug succeeds in mid-stage trial

(Reuters) - Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.